MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Gesloten

SectorGezondheidszorg

2.68 -1.47

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.67

Max

2.73

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.9M

247K

Verkoop

5.1M

62M

Winstmarge

0.395

Werknemers

181

EBITDA

-6.1M

7.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+156.41% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-162M

726M

Vorige openingsprijs

4.15

Vorige sluitingsprijs

2.68

Nieuwssentiment

By Acuity

94%

6%

356 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Akebia Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 sep 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 sep 2025, 23:43 UTC

Populaire aandelen

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 sep 2025, 23:12 UTC

Winsten

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 sep 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Lifeway Foods, Danone Agree to Stay Litigation

30 sep 2025, 21:17 UTC

Winsten

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 sep 2025, 20:47 UTC

Winsten

Nike 1Q Sales Rise as Turnaround Progresses

30 sep 2025, 23:45 UTC

Marktinformatie

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 sep 2025, 23:45 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 sep 2025, 23:26 UTC

Acquisities, Fusies, Overnames

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 sep 2025, 23:26 UTC

Acquisities, Fusies, Overnames

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 sep 2025, 23:25 UTC

Acquisities, Fusies, Overnames

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 sep 2025, 23:24 UTC

Acquisities, Fusies, Overnames

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 sep 2025, 23:24 UTC

Acquisities, Fusies, Overnames

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 sep 2025, 22:54 UTC

Marktinformatie

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 sep 2025, 22:38 UTC

Winsten

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sep 2025, 22:32 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 sep 2025, 22:32 UTC

Marktinformatie

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 sep 2025, 22:03 UTC

Acquisities, Fusies, Overnames

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sep 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sep 2025, 21:02 UTC

Winsten

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sep 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

30 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

30 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 sep 2025, 20:28 UTC

Winsten

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 sep 2025, 20:22 UTC

Winsten

Nike 1Q North America Revenue $5.02B >NKE

30 sep 2025, 20:22 UTC

Winsten

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 sep 2025, 20:22 UTC

Winsten

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 sep 2025, 20:22 UTC

Winsten

Nike 1Q Greater China Revenue $1.51B >NKE

30 sep 2025, 20:19 UTC

Winsten

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Peer Vergelijking

Prijswijziging

Akebia Therapeutics Inc Prognose

Koersdoel

By TipRanks

156.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD  156.41%

Hoogste 8 USD

Laagste 6 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Akebia Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.345 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

356 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat